Company intelligence / Profile preview
EndoCyclic Therapeutics
Irvine, California, United Statesendocyclictherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing ENDO-205, the first non-hormonal, disease-modifying therapeutic for endometriosis, and ENDO-210, a targeted diagnostic agent for definitive MRI diagnosis. The therapeutic approach targets diseased endometriosis tissue and aims to eradicate lesions without surgery or long-term medication[2].
- Therapeutic areas
- OncologyWomen's Health
- Modalities
- Small moleculespH-sensitive peptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on EndoCyclic Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EndoCyclic Therapeutics.